Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CERo Therapeutics Holdings ( (CERO) ) just unveiled an announcement.
On July 11, 2025, CERo Therapeutics Holdings entered into a new purchase agreement with an institutional investor to issue and sell up to $17,490,897 of its common stock, continuing its equity line program. This agreement allows the company to strategically manage its stock sales while ensuring the investor’s ownership does not exceed 4.99% of outstanding shares, potentially impacting the company’s financial flexibility and market positioning.
The most recent analyst rating on (CERO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on developing therapeutic solutions. The company is involved in issuing and selling common stock as part of its financial strategy.
Average Trading Volume: 1,209,467
Technical Sentiment Signal: Sell
Current Market Cap: $4.5M
See more insights into CERO stock on TipRanks’ Stock Analysis page.